Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 310 matching trials from the live ClinicalTrials.gov search.

Filters: "ALK" Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: X-396 (ensartinib), crizotinib; Drug
Lead sponsor: Xcovery Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 4
States / cities: Tampa, Florida • Athens, Georgia • St Louis, Missouri + 1 more

Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Interventions: ATA3219; Drug
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Orlando, Florida • Louisville, Kentucky • Philadelphia, Pennsylvania + 1 more

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7,458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1655
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more

Conditions: Non-small Cell Lung Cancer
Interventions: Alectinib, Cobimetinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: Ezabenlimab, BI 754111; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more

Conditions: Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions: Ipilimumab, Placebo, Paclitaxel, Carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 78
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more

Conditions: Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
Interventions: Alectinib, Duvelisib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Tiragolumab, Matching Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: Denver, Colorado • New Haven, Connecticut • St. Petersburg, Florida + 5 more

Conditions: Advanced/Metastatic Malignant Solid Tumors
Interventions: HLX43, HLX10; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more

Conditions: ALK Positive Malignancies
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Loma Linda, California • Aurora, Colorado + 2 more

Conditions: Castration-resistant Prostate Cancer
Interventions: Crizotinib, Enzalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 36
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 28 more

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions: ILKN421H, Pembrolizumab; Drug
Lead sponsor: iLeukon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • Fort Worth, Texas

Conditions: Allergy
Interventions: ALK Ragweed Tablet; Biological
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non-small Cell Lung Cancer, Carcinoma, NSCLC
Interventions: Ensartinib, Durvalumab; Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Decision support tool; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Alectinib, Bevacizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: Erlotinib, PF-02341066; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 16
States / cities: Birmingham, Alabama • Orange, California • Fort Lauderdale, Florida + 6 more

Conditions: Solid Tumors, CNS Tumors
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: ALK-positive Non-small Cell Lung Cancer
Interventions: Ceritinib, Stereotactic ablative body radiation; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancers With NTRK, ROS1, or ALK Gene Fusions
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: San Diego, California

Conditions: Peanut Allergy
Interventions: Peanut SLIT-tablet, Placebo; Biological · Other
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 33
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Lorlatinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Safety of ALK Ragweed Tablet

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions